Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. Yao J, et al. Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161. Oncologist. 2022. PMID: 35983951 Free PMC article. Review.
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Kulke MH, et al. Among authors: yao jc. J Clin Oncol. 2011 Mar 1;29(7):934-43. doi: 10.1200/JCO.2010.33.2056. Epub 2011 Jan 24. J Clin Oncol. 2011. PMID: 21263089 Free PMC article.
Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Yao JC, et al. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. N Engl J Med. 2011. PMID: 21306238 Free PMC article. Clinical Trial.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Pavel ME, et al. Among authors: yao jc. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. Lancet. 2011. PMID: 22119496 Clinical Trial.
Neuroendocrine tumors.
Kulke MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW 2nd, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA; National Comprehensive Cancer Networks. Kulke MH, et al. Among authors: yao jc. J Natl Compr Canc Netw. 2012 Jun 1;10(6):724-64. doi: 10.6004/jnccn.2012.0075. J Natl Compr Canc Netw. 2012. PMID: 22679117
In reply.
Yao J, Reidy Lagunes D, Kulke MH. Yao J, et al. Oncologist. 2013;18(11):1240-1. doi: 10.1634/theoncologist.2013-0242. Oncologist. 2013. PMID: 24218002 Free PMC article.
12,640 results
You have reached the last available page of results. Please see the User Guide for more information.